Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PKE reports today carrying a short interest profile that has been unwinding steadily, even as the stock has slipped 5% over the past month to close at $29.66. Shorts representing 6.3% of the free float have been pulled back nearly 5% over the past week, continuing a trend that has run alongside a cost-to-borrow rate easing to just 0.37%, its lowest level in months. The lending pool is effectively wide open: availability has surged 92% in a week to over 1,070% of outstanding short interest, meaning there are more than ten shares available to borrow for every one currently shorted. Options traders are not adding to the caution either. The put/call ratio of 0.15 is barely above its 20-day average, sitting near the lowest end of the past 52 weeks, suggesting almost no demand for downside protection into the print.
The fundamental debate heading into results is a genuine one. Bulls point to FQ1 momentum that was hard to dismiss: commercial aircraft sales up 26% to $9.3 million, military revenue up 16%, and adjusted EBITDA jumping 54% year-over-year to $4.58 million as the mix tilted toward high-margin ablative materials. The balance sheet is debt-free with $89.4 million in cash and a $51.4 million backlog, giving the company capacity to fund new plants in Tulsa and the Midwest without stretching. Coverage is thin but consistent: Needham reiterated its Buy at $43 in July, and Citizens initiated at Market Outperform with a $42 target in June. Both targets sit roughly 40% above the current price, a gap that speaks to where sentiment was building before the stock's recent pullback. Bears counter that business aircraft remains a shrinking drag, down 11% year-over-year to about $1.1 million, and flag execution risk around the capacity expansion. The macro backdrop for defense spending also introduces uncertainty around programme timelines.
The ownership picture has one notable development. Brandes Investment Partners, already the largest external holder at 12.2% of the class per its most recent Schedule 13G/A filed August 13, trimmed its stake from a prior 14.0%. The position remains substantial. FMR and State Street each crossed the 5% threshold in new Schedule 13G filings lodged in August, confirming that three large institutions now sit above that level. The most recent insider activity, from August, was dominated by option exercises and same-day sales by CEO Brian Shore and President Mark Esquivel, with net insider disposals of roughly $4.5 million on a 90-day basis. The transaction codes were all mechanical (M-type exercises, not open-market purchases), so these are compensation mechanics rather than a directional signal on conviction.
The print will test whether the FQ1 margin and revenue momentum has carried into the next quarter, and whether management's capacity expansion plans are sufficient to justify a valuation that, even after a 5% monthly slide, still prices in sustained double-digit growth.
See the live data behind this article on ORTEX.
Open PKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
